Title of article
Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
Author/Authors
Hashemzadeh, Nastran Research Center for Pharmaceutical Nanotechnology - Biomedicine Institute - Tabriz University of Medical Sciences , Adibkia, Khosro Research Center for Pharmaceutical Nanotechnology - Biomedicine Institute - Tabriz University of Medical Sciences , Barar, Jaleh Research Center for Pharmaceutical Nanotechnology - Biomedicine Institute - Tabriz University of Medical Sciences
Pages
3
From page
1
To page
3
Abstract
Trafficking of macromolecular immunotherapy agent into the tumor microenvironment (TME) is a challenging issue. In the TME, cancer cells exploit indoleamine 2, 3-dioxygenase (IDO), as a cytosolic enzyme that catalyzes the L-tryptophan (Trp) through the kynurenine (Kyn) pathway, which could negatively regulate the activity of T cells. Thus, Trp/Kyn pathway, can be targeted with novel treatment modalities such as IDO1 inhibitor to benefit patients with aggressive solid tumors.
Keywords
Indoleamine 2 , 3-dioxygenase , Kynurenine , Immunotherapy , IDO inhibitor , Solid tumors , Cancer therapy
Journal title
Bioimpacts
Serial Year
2019
Record number
2499989
Link To Document